Back to search
FDAFDA · Food and drugs·Recall number D-1494-2020

Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl. oz. (473 mL), Rx only, Pharmaceutical Associates, Inc. Greenville, SC 29605, NDC 0121-0810-16

Published August 19, 2020 · Recall initiated: August 4, 2020

Summary

FDA records drug Class II recall D-1494-2020, published August 19, 2020 and initiated August 4, 2020. Recalling firm: PAI Holdings, LLC. dba Pharmaceutical Associates Inc; Status: Terminated; Reported quantity: 7416 bottles; Lot: Lot: B973, Exp 11/20. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent drug: Out of specification for assay at the 15-month test interval.

What to do

Voluntary: Firm initiated · Letter

Get an email if NYSTATIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NYSTATIN
Manufacturer
PAI Holdings, LLC. dba Pharmaceutical Associates Inc
Distributor
Nationwide USA
UPC
0301210810022
Lot
Lot: B973, Exp 11/20
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl. oz. (473 mL), Rx only, Pharmaceutical Associates, Inc. Greenville, SC 29605, NDC 0121-0810-16 recalled?

Yes. FDA published recall D-1494-2020 on August 19, 2020. Reported hazard: Subpotent drug: Out of specification for assay at the 15-month test interval.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NYSTATIN. UPC: 0301210810022.